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ABSTRACT
Muscarinic agonist-induced contraction of the ciliary muscle is generally
believed to increase aqueous outflow facility and effect accommodation. We used
cultured human ciliary muscle cells as a model to study the muscarinic receptor
subtype(s) involved in the contractile response of the muscle. Thus, a single cell
contraction assay for these muscle cells was developed. And since agonist-induced
contraction of smooth muscles is expected to involve the activation of phospholipase
C (PLC), we also monitored the PLC activity in these cells. Carbachol caused
contraction of the muscle cells in a dose-dependent and time-dependent manner with
an estimated EC50 of 1-3 pH. The contractile effect of 100 uM carbachol was
antagonized by pretreatment of atropine (1 uM) and 4DAMP (10 nM, antagonist
selective for the Ml and M3 receptors) but not by pirenzepine (10 pH, antagonist
selective for the Ml receptor), suggesting the involvement of the M3 but not the Ml
muscarinic receptor. M3 receptor is also essential for the carbachol-induced PLC
activation in the ciliary muscle cells, as indicated by the activity profiles of
receptor subtype selective antagonists. For example, the stimulative effect of
carbachol (EC50 - 20 pM) was antagonized by pirenzepine (pKi = 6.8), HHSiD (pKi =
7.6), 4DAMP (pKi - 9.5) and methoctramine (pKi < 6). Thus, these results indicate
that an M3-like receptor subtype is essential in mediating the muscarinic agonists-
induced functional changes, such as PLC activation or muscle contraction, in the
ciliary muscle.
INTRODUCTION
Muscarinics, such as pilocarpine and carbachol, have been used topically as
ocular hypotensive agents for more than a century (1-3). They lower intraocular
pressure (IOP) presumably by contracting the ciliary muscle (4) , which in turn
increases the trabecular outflow of aqueous humor.
Topical administration of cholinergic agonists is safe. Due to the low
systemic concentration of the drug after topical uses, systemic side effects rarely
occur (3). However, ocular side effects of muscarinic agonists are common, which
limits the acceptability of these compounds. Adverse reactions to pilocarpine and
carbachol include miosis (due to the contraction of the iris sphincter), myopia
(contraction of the ciliary muscle), temporal and supraorbital headache (supposedly
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secondary to the contraction of the ciliary muscle). Attempts, such as the
exploitation of pharmacokinetic properties of the compounds, have been made to
minimize these side effects, with only limited success. However, there is recent
evidence suggesting that separation of the IOP-lowering effect and ocular side
effects of cholinergics is feasible. For example, aceclidine, another muscarinic
agonist, is as effective and potent as pilocarpine at lowering IOP in humans, but
is much more potent as a miotic and does not produce much accommodation (5-8). In
the monkey, aceclidine also increases facility of aqueous outflow with minimal
accommodative effect (9). Furthermore, in the monkey, the increase in outflow
facility produced by pilocarpine was reversed by atropine in two phases, a fast
phase and a slow one. Yet the reversal of accommodation exhibited only a fast phase(10). This separation of muscarinic effects could be explained by the presence of
different muscarinic receptor subtypes, each of which mediates different actions of
the agonists.
Indeed, during the last several years, messenger RNAs of five muscarinic
receptor subtypes were discovered (11, 12). They are named ml to m5, in which ml,
m2 and m3 correspond to the Ml, M2 and M3 receptor subtypes that were defined by
affinity profiles of selective antagonists. Since both carbachol and pilocarpine
are nonspecific among the five receptors, it is possible, as stated before, that the
IOP-lowering effect and the ocular side effects of muscarinics involve different
receptor subtypes. If this hypothesis is true, then a selective agonist properly
chosen could be highly effective in lowering IOP and have minimal miotic or
accommodative actions. Initial steps in testing this hypothesis are to define the
distribution of the various receptor subtypes in the eye and to confirm the
involvement of the receptors in the various ocular actions of muscarinic agonists.
Several published studies tried to address these issues (13-17) . In this report we
used the cultured human ciliary muscle cells and attempted to elucidate the
muscarinic receptor subtype that mediates the carbachol-induced contraction of the
muscle cells as well as the activation of phospholipase C (PLC).
METHODS
Cell Culture
Human ciliary muscle cells were isolated and characterized as described earlier
(18). The cells were cultured at 37°C and 5% C02, in Dulbecco's modified Eagle's
medium (Gibco BRL, Grand Island, NY) with 10% fetal calf serum (Hyclone, Logan, UT) ,
supplemented with 4 mM L-glutamine (Gibco BRL) and 50 /jg/ml gentamicin (Gibco BRL).
Cells were subcultured following trypsinization. They were shown to be free of
mycoplasma contamination (assayed by MycoTect Mycoplasma Detection Kit, Gibco BRL).
Cell Contraction Assay
Single cell contraction assay of the ciliary muscle cells were performed
according to the procedure of Pang et al (19). Briefly, on the day of study, the
cells (of passages 8 to 12) were partially detached from the plastic cultured dish
(Costar, Cambridge, MA) by replacing the medium with a nonenzymatic cell
dissociation buffer (catalog no. C-5914, Sigma, St Louis, MO) and incubated at 37°C
for 30-40 min. Carbachol (Research Biochemicals Inc., Natick, MA) was then added.
In some experiments, an antagonist such as atropine sulfate (Sigma), Pirenzepine HC1(Research Biochemicals Inc.) or 4-diphenylacetoxy-N-methylpiperidine methiodide
(4DAMP, Research Biochemicals Inc.) was added 5 min before the addition of
carbachol. Photomicrographs were taken at time intervals throughout the
experiments. The cross-sectional surface areas of the cells were obtained by
projecting the cell images of each photograph through a video camera onto a monitor
screen of a personal computer. The cell images were then manually outlined, and the
surface areas enclosed by the outlines were quantified using an image-analysis
software (BioQuant, R & M Biometrics, Inc., Nashville, TN). A decrease in cross-
sectional surface area of the cells was interpreted as an indication of cell
contraction. To normalize the changes, relative areas of the cells were used. The
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relative area of a cell was defined as the surface area at the indicated time point
divided by the surface area at time 0 of the same cell.
Phospholipase C Assay
For PLC activity assay, the ciliary muscle cells (of passages 10 to 14) were
cultured on 24-well plates (confluent monolayer, 7 to 8 x 105 cells/well) and
incubated with [3H] myoinositol (Amersham, Arlington Heights, IL, 5 uCi/ml/well) in
a serum-free mixture (1:1) of Dulbecco's modified Eagle's medium: nutrient mixture
F12 for two days. On the day of study, free radioactive inositol was removed by
rinsing the cells four times with 1 ml serum-free medium containing 10 mM LiCl
(Mallinckrodt, Paris, KY) . Agonists were added 10 min later. In some studies,
antagonists were added 5 min prior to agonists. At the indicated time after the
agonist was added, the reaction was stopped by replacing the medium with 0.5 ml of
5% perchloric acid (Baker, Philipsburg, NJ) . Samples were placed on ice for at
least 10 min. The perchloric acid was removed from the cell lysate by extraction
with 2 ml 1:1 mixture of 1,1,2-trichloro-trifluoro-ethane (Sigma):tri-n-octylamine(Sigma). After extraction, the aqueous layer was loaded onto 1 ml columns of
formate-equilibrated BioRad AG 1x8 anion exchange resin (BioRad, Richmond, CA) . The
columns were washed with 10 ml of water, followed by 8 ml of 50 mM formic acid(Sigma). The bound inositol phosphates were eluted with 4 ml of 1.2 M ammonium
formate (Sigma) in 0.1 M formic acid and the incorporated tritium was monitored by
scintillation counting. In recent experiments, this assay procedure was simplified
such that the reaction was stopped by replacing the cell medium with 0.5 ml of 50
mM formic acid instead of perchloric acid. The cell lysate was then directly loaded
onto the anion exchange column and eluted as described. The two assay procedures
generated similar results.
Materials
Other compounds, such as p-fluoro-hexahydro-sila-difenidol (HHSiD),
methoctramine HC1, oxotremorine-M, pilocarpine HC1 and pirenzepine 2HC1 were
obtained from Research Biochemicals Inc. Aceclidine was obtained from Alcon, Ft
Worth, TX.
RESULTS
Cell Contraction
As shown in Figure 1, the cross-sectional surface areas of most of the human
ciliary muscle cells decreased 5 and 10 min after carbachol (100 pM) treatment. No
significant change in cell area was observed during the 5-min period before the
agonist was added. This change in cell surface area was interpreted as an
indication of contraction. The cellular contraction was obvious within 1 min of
carbachol treatment, and the surface area stabilized at approximately 10 min after
the application of the muscarinic agonist (19). This carbachol-induced contraction
was dose dependent. As demonstrated in Figure 2A, 0.1 /jM of carbachol was
ineffective in producing contraction of the muscle cells, whereas 1 /jM caused a
partial contraction (ie, the area of the cells decreased to 70% of the initial
surface area). Higher concentrations of carbachol induced additional contraction
of the cells: 10 and 100 uM of the agonists reduced the cells to 40-50% of their
original sizes. A dose-response curve could be constructed by plotting the relative
areas of the cells 10 min after carbachol treatment versus the concentration of
carbachol used (Fig. 2B). The effective dose of carbachol for 50% of the maximal
effect was estimated to be 1-3 uM. The carbachol-induced contraction was apparently
mediated by muscarinic cholinergic receptors. Pilocarpine, another muscarinic
agonist, also caused the isolated ciliary muscle cells to contract (relative area
at 10 min, 60 ± 5% [mean ± SEM, n=7] after 0.1 mM pilocarpine treatment).
Furthermore, the effect of 1 mM carbachol was completely blocked by pretreatment of.
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FIGURE 1
. Photomicrographs of human ciliary muscle cells during contraction induced
by carbachol.
the cells with 1 pM of atropine, a muscarinic antagonist (data not shown).
To clarify the involvement of the muscarinic receptor subtypes in the induction
of contraction, receptor-selective antagonists were used to block the effect of
carbachol. 4DAMP, an antagonist selective for both Ml and M3 receptor subtypes, was
very potent in preventing the carbachol-induced contraction (Fig. 3). Thus,
pretreatment of the cells for 5 min with 0.1 nM 4DAMP completely blocked the
contractile effect of 10 ßM of carbachol but not that of 100 pM or 1 mM of carbachol(Fig. 3B) . Effects of higher concentrations of carbachol were antagonized by
increasing amounts of 4DAMP (Fig. 3C and 3D) . Dose response relationship of
carbachol in the presence of various concentrations of 4DAMP summarizes these
results (Fig. 5, upper panel). It is obvious that pretreatment of 4DAMP (0.1 to 10
nM) caused sequential rightward shifts of the potency of carbachol, indicating that
4DAMP is a potent and competitive antagonist for the muscarinic effect. The pA2
calculated (according to ref. 20) from the observed shifts of the carbachol potency
is 10.5. Since 4DAMP is an antagonist for both the Ml and M3 receptor subtypes, it
is necessary to further differentiate the involvement of the two receptor subtypes.
Pirenzepine is another potent muscarinic antagonist. At low concentrations, it is
selective for the Ml receptor (pKi = 8)(11), whereas at higher concentrations (100
nM or higher), it also binds significantly to other muscarinic receptors and thus
becomes nonselective. In the isolated human ciliary muscle cells, pirenzepine, at
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FIGURE 2. Effects of various doses of carbachol on ciliary muscle cell contraction.(A) Time courses of changes. Symbols represent the mean ± SEM of seven cells at
each dose. At 15 min, carbachol (100 ßft) was added to some of the samples to
demonstrate their full contraction capability. (B) Dose-response curve of carbachol.
The relative areas at 10 min after carbachol treatment are presented here. Symbols
represent the mean ± SEM of seven cells. Reprinted with permission from ref. 19.
concentrations 10,000 fold higher than that of 4DAMP, was effective in blocking the
contraction induced by carbachol (Fig. 4 & 5, lower panel). The calculated pA2 for
pirenzepine in this assay is 7.2, indicating that an Ml receptor was not essential
in mediating the carbachol action.
Phospholipase C Activity
In smooth muscle cells, contraction can be a result of activation of PLC by
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FIGURE 3. Effects of 4DAMP on the contractile action of carbachol (CCH). At the
indicated time points, cells were pretreated with vehicle or 4DAMP before the
addition of carbachol. The pretreatments were vehicle (A), 0.1 nM 4DAMP (B), 1 nM
4DAMP (C) or 10 nM 4DAMP (D) . Dosages of carbachol used were 0 uM (closed
triangles) , 10 uM (open triangles) , 100 pl/l (closed circles) and 1 mM (open circles) .
Each symbol represents mean relative area ± SEM of seven cells.
agonists. Consequently, the effects of muscarinic agonists on PLC in these cells
were tested. Carbachol (100 uM) treatment activated the PLC for at least two hours
as indicated by the continuous accumulation of inositol phosphates (data not shown).
During this period, no significant desensitization of the receptor or depletion of
the enzyme substrate was detected. Therefore, for the sake of convenience, one hour
was chosen as the standard incubation time for the following studies. Muscarinic
agonists, such as carbachol, oxotremorine-M, pilocarpine and aceclidine, stimulated
the production of inositol phosphates in a dose dependent manner. Typical dose-
response curves are shown in Figure 6. Carbachol (1 mM) increased the accumulation
of inositol phosphates in human ciliary muscle cells by approximately 10 fold from
a basal level of 439 ± 67 cpm/well (mean ± SEM from 10 duplicated studies) to 4633
± 593 cpm/well. Similar maximal stimulation was also seen with oxotremorine-M,
another full agonist of the muscarinic receptor. Pilocarpine and aceclidine are
partial agonists of the muscarinic agonist, such that their maximum effects are only
fractions of that of a full agonist. We also observed the same phenomenon in their
stimulation of PLC in the ciliary muscle cells. Table 1 presents the mean
calculated EC50 values and the maximal effects of these compounds in relation to
that of carbachol.
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FIGURE 4. Effects of pirenzepine (przp) on the contractile action of carbachol(CCH). At the indicated time points, cells were pretreated with vehicle or
pirenzepine before the addition of carbachol. The pretreatments were vehicle (A),
1 /jM pirenzepine (B) , 10 ßM pirenzepine (C) or 100 ßM. pirenzepine (D) . Dosages of
carbachol used were 1 ßM (closed triangles), 10 ßM (open triangles) , 100 ßM (closed
circles) and 1 mM (open circles). Each symbol represents mean relative area ± SEM
of seven cells.
To clarify the involvement of the muscarinic receptor subtypes in the
activation of PLC, the following receptor-selective antagonists were used to block
the effect of carbachol: pirenzepine, selective for the Ml receptor subtype;
methoctramine, selective for M2 ; HHSiD, selective for M3; 4DAMP, for both Ml and M3;
and atropine, a nonspecific antagonist. Figure 7 shows typical inhibition curves
for some of the antagonists tested. The inhibition coefficient (Ki) of each compound
was calculated with the equation: Ki=IC50/(l+[carbachol]/(EC50 of carbachol)) (21).
Results are presented in Table 2. It is clear that the most potent subtype-
selective antagonists in preventing the carbachol-induced PLC activation were 4DAMP
and HHSiD, suggesting that the M3 receptor subtype was essential in mediating the
muscarinic effect in the ciliary muscle cells.
DISCUSSION
In the cultured human ciliary muscle cells, muscarinic cholinergic agonists,
such as carbachol, at concentration as high as 1 mM, did not affect the activities
of nucleotide cyclases though adenylyl and guanylyl cyclase activities were detected
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FIGURE 5. Dose response relationship of carbachol in the presence of 4-DAMP (upper
panel) or pirenzepine (lower panel). Cells were pretreated with different
concentrations of 4-DAMP or pirenzepine for 5 min before the addition of carbachol.
The relative areas at 10 min after carbachol treatment are presented here. Bars
represent mean ± SEM of seven cells.
in these cells as indicated by the stimulation induced by isoproterenol or sodium
nitroprusside, respectively (unpublished observation). Instead, muscarinics
activated PLC, increased intracellular concentration of calcium (unpublished
observation) and caused cell contraction. We have reported here the results of
their effects on PLC and contraction of these cells.
Carbachol decreased the cross-sectional surface area of the ciliary muscle
cells. We interpreted this surface area change as an indication of cell contraction
instead of volume change, because incubation of the cells in a hyperosmotic
solution, a treatment known to cause shrinkage of the cell volume, only flattened
the cells without significant decrease of the cross-sectional surface area (19) .
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FIGURE 6. Dose response curves of muscarinic agonists on the activation of
phospholipase C in the human ciliary muscle cells. Each symbol represents datum
from a single sample.
TABLE 1
Activation of Phospholipase C in The Human Ciliary Muscle Cell
Agonist mean EC50 log[EC50] ± SEM Max* ± SEM
(%)
Carbachol
Oxotremorine-M
Aceclidine
Pilocarpine
10
3
3
3
20.0 ßM
6.9 ßM
13.1 ßM
2.1 ßM
-4.70 ± 0.06
-5.15 ± 0.03
-4.88 ± 0.06
-5.57 ± 0.12
100
121 ± 2
31 ± 1
13 ± 1
*: Maximal effect of the agonists as compared to that of carbachol, which defines
100%.
TABLE 2
Inhibition coefficients of Selective Muscarinic Antagonists on
Carbachol-induced Phospholipase C in The Human Ciliary Muscle Cells
Antagonist
Atropine
Pirenzepine
4DAMP
HHSiD
Me thoc tramine
pKi ± SEM
9.12 ± 0.10
6.76 ± 0.05
9.46 ± 0.24
7.57 ± 0.11
< 6.0
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FIGURE 7. Inhibition curves of muscarinic antagonists on the carbachol-induced
activation of phospholipase C in the human ciliary muscle cells. The cells were
pretreated with various concentrations of the antagonists before treated with 100
pH of carbachol. Each symbol represents a single sample.
Thus, carbachol induced contraction of ciliary muscle cells in a dose-dependent and
time-dependent manner. Its effect was mimicked by pilocarpine and antagonized by
atropine, indicating that the effect was mediated by a muscarinic cholinergic
receptor. Similarly, the activation profile of PLC by the various agonists also
agreed with published characteristics of muscarinic receptor-mediated actions.
In other smooth muscles, the activation of PLC by agonists can cause
contraction. It is likely, yet unproven, that in the ciliary muscle cells, the
contraction induced by muscarinic agonists is the result of the activation of PLC.
The difference in the EC50 values of carbachol for the activation of PLC and
contraction can be explained by the "spared receptor" concept, or, more accurately,
the "spared second messenger" concept. Thus, activation of only a small fraction
of the PLC may be sufficient to induce a full contraction response. Nevertheless,
we cannot exclude the possibility that the two muscarinic actions were activated
independently. Clarification awaits future studies.
Both the carbachol-induced changes in PLC activity and cell contraction were
competitively inhibited by antagonists. The relative potency of the antagonists for
PLC activation was 4DAMP = atropine > HHSiD > Pirenzepine » methoctramine.
Accordingly, in the contraction assay, 4DAMP was a much more potent antagonist than
pirenzepine. Based on the affinity profiles of these selective antagonists, the M3
or an M3-like receptor subtype was essential in the carbachol-induced activation of
PLC and cell contraction. These findings agree with the published data in that the
M3 receptor is important for functions of the ciliary muscle. In the human ciliary
muscle, by using autoradiography and in situ hybridization, Gupta et al showed that
ml/Ml and m3/M3 receptor subtypes are present (14). The messenger RNA of the m3
receptor was detected by Northern blot in the cultured human ciliary muscle cells
and post mortem tissue (13,15). Furthermore, WoldeMussie et al (17) demonstrated
that the muscarinic binding sites in these cells were most likely M3 receptors and,
similar to our findings, the muscarinic agonist-induced PLC activation was mediated
by an M3-like receptor. Interestingly, the m3/M3 receptor is also shown to be the
most common muscarinic receptor subtype in the iris sphincter (14,17), implying that
this receptor likely mediates the muscarinic agonist-induced miosis. Indeed, Gabelt
and Kaufman (16) demonstrated that in the perfused monkey eye, 4DAMP was the most
potent antagonist in blocking the increase in aqueous outflow facility,
accommodation and miosis caused by pilocarpine, showing that an M3-like receptor is
essential in all of the actions of pilocarpine. Thus, it appears that the M3
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receptor mediates muscarinic agonist-induced contractions of both the iris sphincter
and the ciliary smooth muscles. If it is proven true, separation of the IOP-
lowering effect and the ocular side effects of muscarinic compounds by using
receptor subtype selective agonists will be theoretically impossible. This
conclusion cannot reconcile with findings that aceclidine has different potencies
for miosis, accommodation and outflow facility (5-9). It may also contradict the
apparent two-component mode of the pilocarpine-induced increase in aqueous outflow
facility (10). A potential explanation is that structures, which express other
receptor subtypes, besides the ciliary muscle are also involved in the cholinergic-
mediated aqueous outflow effects. Clarification of this hypothesis requires future
studies on other ocular tissues, such as the trabecular meshwork, and in vivo
experiments using receptor subtype-selective agonists when they become available.
ACKNOWLEDGEMENTS
We thank Debra L. Shade and Peggy E. Magnino for superb technical assistance.
REFERNCES
1. Nardin, G.F., Zimmerman, T.J., Zaita, A.H., and Felts, K. Ocular cholinergic
agents. In The glaucomas, Ritch, R., and Shields, M.B., eds. C.V. Mosby,
St Louis, 1989, p. 515-521.
2. Hoskins, H.D., and Kass, M.A. In Becker-Shaffer's diagnosis and therapy of the
glaucomas. C.V. Mosby, St Louis, 1989, p. 420-434.
3. Liopold, I.H. The use and side effects of cholinergic agents in the management
of intraocular pressure. In Glaucoma: Applied pharmacology in medical
treatment. Drance, S.M., and Neufeld, A.H,, eds. Grune & Stratton, Orlando,
1984, p. 357-393.
4. Bill, A. Aqueous humor dynamics in monkeys. Exp. Eve Res.. 11:195-206, 1971.
5. Lieberman, T.W., and Leopold, I.H. The use of aceclidine in the treatment of
glaucoma. Its effect on intraocular pressure and facility of aqueous humor
outflow as compared to that of pilocarpine. Am. J. Ophthalmol.. 64:405-415,
1967.
6. Romano, J.H. Double-blind cross-over comparison of aceclidine and pilocarpine
in open-angle glaucoma. Br. J. Ophthalmol.. 54:510-521, 1970.
7. Fechner, P.U., Teichman, K.D., and Weyrauch, W. Accommodative effects of
aceclidine in the treatment of glaucoma. Am. J. Ophthalmol.. 79:104-106, 1975.
8. Keren, G., and Treister, G. Effect of aceclidine (+) isomer and pilocarpine
on the intraocular pressure decrease and the miosis in glaucomatous eyes.
Effect on accommodation in normal eyes of young subjects. Ophthalmologica.
180:181-187, 1980.
9. Erickson-Lamy, K.A., and Schroeder, A. Dissociation between the effect of
aceclidine on outflow facility and accommodation. Exp. Eye Res.. 50:143-147,
1990.
10. Bàràny, E.H. The mode of action of pilocarpine on outflow resistance in the
eye of a primate (Cercopithecus ethiops). Invest. Ophthalmol.. 1:712-727,
1962.
11. Birdsall, N.
, Buckley, N., Doods, H. , et al. Nomenclature for muscarinic
135
receptor subtypes recommended by symposium. Trends Pharmacol. Sei..
10(suppl.):vii, 1989.
12. Goyal, R.K. Muscarinic receptor subtypes: physiology and clinical
implications. New England J. Med.. 15:1022-1028, 1989.
13. Erickson-Lamy, K.A., Chen, M.C., and Hernandez, M.R. Expression of muscarinic
receptor messenger RNA in cultured ciliary muscle cells. Invest. Ophthalmol.
Vis. Sei.. 32:833, 1991.
14. Gupta, N., Prasad, S., McAllister, R., Drance, S.M., and Cynader, M.S. The
distribution of M3 muscarinic receptor subtype and m3 messenger RNA in human
ocular structures. Soc. Neurosci. Abs.. 17:587, 1991.
15. Bogardus, A.M., Feldmann, B.J., WoldeMussie, E., and Gil, D.W. Muscarinic
receptor subtypes in human eye. Soc. Neurosci. Abs.. 17:587, 1991.
16. Gabelt, B.T., and Kaufman, P.L. Inhibition of outflow facility and
accommodative and miotic responses to pilocarpine in rhesus monkeys by
muscarinic receptor subtype antagonists. J. Pharmacol. Exp. Ther., 263:1133-
1139, 1992.
17. WoldeMussie, E., Feldmann, B.J., and Chen, J. Characterization of muscarinic
receptors in cultured human iris sphincter and ciliary smooth muscle cells.
Exp. Eve Res.. 56:385-392, 1993.
18. Tamm, E., Flügel, C., Baur, A., and Lütjen-Drecoll, E. Cell cultures of human
ciliary muscle: Growth, ultrastructural and immunocytochemical characteristic.
Exp. Eye Res.. 53:365-387, 1991.
19. Pang, I.-H., Shade, D.L., Tamm, E., and DeSantis, L. Single-cell contraction
assay for human ciliary muscle cells: effect of carbachol. Invest. Ophthalmol.
Vis. Sei.. 34:1876-1879, 1993.
20. Arunlakshana, 0., Schild, H.O. Some quantitation uses of drug antagonists.
Br. J. Pharmacol.. 14:48-58, 1959.
21. Craig, D.A. The Cheng-Prusoff relationship: something lost in the translation.
Trends Pharmacol. Sei.. 14:89-91, 1993.
22. Pang, I.-H., Shade, D., Tamm, E., and DeSantis, L. Contraction of human
ciliary muscle cell induced by muscarinic agonists. Invest. Ophthalmol. Vis.
Sei.. 33:731, 1992.
23. Matsumoto, S., Magnino, P.E., Miggans, S.T., Shade, D.L., DeSantis, L., Pang,
I-H. Receptor-mediated activation of phospholipase C in cultured non-
transformed and transformed human ciliary muscle cells. Ocular Cell Mol. Biol.
Svm. Abs.. 1:26, 1992.
Received: August 11, 1993
Accepted for Publication: September 21, 1993
Reprint Requests: Iok-Hou Pang, Ph.D.
Alcon Laboratories, R3-24
6201 South Freeway
Fort Worth, Texas 76134
U.S.A.
Portions of this manuscript were published in references 19, 22 & 23.
136
This article has been cited by:
1. Clare Johnson, Janet Smereck. 2012. Unilateral Mydriasis Due to a Topical “Anti-sweat”
Preparation. The Journal of Emergency Medicine . [CrossRef]
2. F Yasui, M Miyazu, A Yoshida, K Naruse, A Takai. 2008. Examination of signalling
pathways involved in muscarinic responses in bovine ciliary muscle using YM-254890,
an inhibitor of the Gq/11 protein. British Journal of Pharmacology 154:4, 890-900.
[CrossRef]
3. Jennifer C. Chen, Katrina L. Schmid, Brian Brown. 2003. The autonomic control of
accommodation and implications for human myopia development: a review. Ophthalmic
and Physiological Optics 23:5, 401-422. [CrossRef]
4. John S. Kennedy, Frank P. Bymaster, Leslie Schuh, David O. Calligaro, George Nomikos,
Christian C. Felder, Mark Bernauer, Bruce J. Kinon, Robert W. Baker, Donald Hay,
H. John Roth, Martin Dossenbach, Christopher Kaiser, Charles M. Beasley, John H.
Holcombe, Mark B. Effron, Alan Breier. 2001. A current review of olanzapine's safety in
the geriatric patient: from pre-clinical pharmacology to clinical data. International Journal
of Geriatric Psychiatry 16:S1, S33-S61. [CrossRef]
5. G W Nietgen, J Schmidt, L Hesse, C W Hönemann, M E Durieux. 1999. Muscarinic
receptor functioning and distribution in the eye: Molecular basis and implications for
clinical diagnosis and therapy. Eye 13:3a, 285-300. [CrossRef]
6. XUN ZHANG, ALISON SCHROEDER, KRISTINE A. ERICKSON. 1999. Effect of
Continuous Administration of a Cholinergic Agonist on [3H]4-DAMP Binding and
m3 mRNA Expression in Cultured Human Ciliary Muscle Cells. Journal of Ocular
Pharmacology and Therapeutics 15:2, 153-163. [Abstract] [Full Text PDF] [Full Text
PDF with Links]
7. HITOSHI ISHIKAWA, LOUIS DeSANTIS, POPAT N. PATIL. 1998. Selectivity of
Muscarinic Agonists Including (±)-Aceclidine and Antimuscarinics on the Human
Intraocular Muscles. Journal of Ocular Pharmacology and Therapeutics 14:4, 363-373.
[Abstract] [Full Text PDF] [Full Text PDF with Links]
